Investigation of pathogenesis and novel treatment for intraocular lymphoma

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592655
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Ophthalmology
• Research Institution: Tokyo Medical University
• Principal Investigator: GOTO Hiroshi 東京医科大学, 医学部, 教授 (10201500)
• Co-Investigator(Kenkyū-buntansha): USUI Yoshihiko 東京医科大学, 医学部, 講師 (50408142) ; YAMAKAWA Naoyuki 東京医科大学, 医学部, 助教 (80599134)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 眼内悪性腫瘍 / 眼内リンパ腫 / ぶどう膜炎 / サイトカイン / ケモカイン / BCA-1 / IL-10

Outline of Final Research Achievements

Five year survival rate of primary intraocular lymphoma (PIOL) is approximately 60 %, because most the patients develop central nervous system lymphoma.
In this study,　we detected new diagnostic marker including BCA-1 by analyzing multiple humoral factors in the vitreous of patients with PIOL. We also identified recurrent copy number gain regions in PIOL, most frequently on chromosome 1q. In addition, there was a correlation between gain of the IL-10 gene and intravitreal interleukin-10 concentration. We have reported that life prognosis of the patients with higher concentration of IL-10 in the vitreous is worse compared to those with lower. These data may contribute to understand pathogenesis of PIOL and develop a novel treatment for patients with PIOL.

Free Research Field

ぶどう膜炎・眼腫瘍・眼窩疾患・眼形成・眼病理